Motor neuron disease presenting with acute hypercapnic respiratory failure
Main Article Content
Abstract
-
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
TsaiM,HsuC,SheuC,BrownRH,Al-ChalabiA.Amyotrophiclateralsclerosis.NEngl J Med 2017;377:1602. https://doi.org/10.1056/NEJMc1710379
Park HS. A case of motor neuron disease presenting as dyspnea in the emergency department. Korean J Fam Med 2012;33(2):110-113. https://doi.org/10.4082/ kjfm.2012.33.2.110
Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry Res 2007;78(6):629-631. https://doi.org/10.1136/jnnp.2006.103564
Su W, Cheng Y, Jiang Z, et al. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis. EBioMedicine 2021;74:103732. https://doi. org/10.1016/j.ebiom.2021.103732
Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55(4):526- 528. https://doi.org/10.1001/archneur.55.4.526
Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo- controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(7-8):610- 617. https://doi.org/10.3109/21678421.2014.959024